Vivos (VIVK) CEO Michael Korenko Buys $11,420 in Stock
Published on · Source: investing.com
AI Summary
Summarized by AI from the source belowMichael Korenko, CEO of Vivos Therapeutics (VIVK), purchased $11,420 worth of company stock. This acquisition underscores Korenko's confidence in the company's future performance. Such insider transactions can influence market perceptions and potentially affect stock price behavior. Investors often monitor insider buying activity as a signal of management's belief in the company's prospects.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Get stories like this as they break
Our Telegram channel posts every market story the moment it is published. Free, and you can mute or leave anytime.
